Chelohart

What is Chelohart?

Chelohart is the heart's bioregulator — the Cytomax derived from cardiac muscle tissue that selectively targets and regulates gene expression in cardiomyocytes (heart muscle cells). The cardiovascular system has two distinct bioregulator compounds in the Khavinson series: Vesugen (KED) for the vasculature (blood vessels, endothelium), and Chelohart for the myocardium (the heart muscle itself). These are complementary compounds addressing different structures within the same organ system.

Cardiac aging is characterised by: progressive cardiac fibrosis (replacement of functional cardiomyocytes with fibrous tissue), reduced cardiomyocyte regenerative capacity (adult cardiomyocytes have extremely limited ability to divide), impaired mitochondrial function in cardiac cells (the heart is the body's most energy-demanding organ per gram of tissue), and age-related left ventricular hypertrophy and stiffening. Chelohart's cardiac-specific peptide complex is theorised to address these aging processes by activating gene expression programs that maintain cardiomyocyte function, reduce fibrotic signalling, and support cardiac energy metabolism.

For the longevity-focused biohacker without diagnosed cardiac disease: Chelohart fits as a preventive cardiac bioregulator, addressing the progressive myocardial aging that begins decades before clinical symptoms appear. The combination of Chelohart (cardiac muscle) + Vesugen (vasculature) represents the most complete cardiovascular bioregulator approach in the series.

How it works

Organ-Specific Chromatin Interaction — Cardiac Targeting

Chelohart's cardiac peptide complex interacts with chromatin in cardiomyocytes, modifying histone acetylation and methylation patterns that activate cardioprotective gene expression programs. The organ-specificity principle: peptides derived from cardiac tissue have structural complementarity to the chromatin regulatory elements in cardiac cells — producing tissue-selective gene expression changes that persist beyond the peptides' physical presence through the epigenetic Cytomax aftereffect.

Anti-Fibrotic Cardiac Effects

Cardiac fibrosis — the pathological accumulation of collagen and fibrous tissue in the myocardium — is one of the primary drivers of heart failure and age-related cardiac dysfunction. Cardiac peptide complexes reduce TGF-β1-driven cardiac fibroblast activation, reduce collagen synthesis in cardiac tissue, and support cardiomyocyte survival over fibroblast replacement. This anti-fibrotic mechanism is the most important cardiac aging intervention that Chelohart addresses.

Cardiomyocyte Energy Metabolism

Cardiomyocytes are the most mitochondria-dense cells in the body. Age-related decline in cardiac mitochondrial function impairs the heart's ability to maintain output under stress. Cardiac bioregulator peptides are theorised to maintain mitochondrial gene expression in cardiomyocytes, supporting the energy production capacity that cardiac performance depends on. This mechanism is complementary to SS-31, which directly protects inner mitochondrial membrane function.

What the research shows

No PubMed-indexed primary literature is linked for this Khavinson Cytomax bioregulator. Prior study cards pointed at unrelated papers; manufacturer summaries and the Khavinson group's clinical reports remain the main accessible sources until verified primary studies are published.

Community knowledge

Chelohart is used primarily by people with cardiovascular history or risk — family history of heart disease, hypertension, or history of cardiac events. The cardiovascular bioregulator stack — Chelohart + Vesugen — addresses both primary cardiac structures and is the most comprehensive cardiovascular bioregulator approach available.